NeuroPace to Present at the 22nd Annual Needham Virtual Healthcare Conference
NeuroPace, a medical device company focused on improving the lives of individuals with epilepsy, announced participation in the 22nd Annual Needham Virtual Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeuroPace, a medical device company focused on improving the lives of individuals with epilepsy, announced participation in the 22nd Annual Needham Virtual Healthcare Conference. The presentation will take place on April 17, 2023, at 7:15 a.m. PT / 10:15 a.m. ET. A live webcast and an archived recording will be available on the company’s website. NeuroPace is renowned for its RNS System, a brain-responsive platform that delivers real-time treatment to help reduce or eliminate seizures. This innovative technology aims to enhance the standard of care for patients suffering from drug-resistant epilepsy and has potential applications for other brain disorders.
Details
News Market Reaction – NPCE
The recorded move for NPCE in the trading session of this news was -5.15%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming 22nd Annual Needham Virtual Healthcare Conference.
Management is scheduled to present on Monday, April 17th, 2023 at 7:15 a.m. Pacific Time / 10:15 a.m. Eastern Time. A live webcast of this event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://investors.neuropace.com.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Investor Contact:
Philip Taylor
Gilmartin Group
investors@neuropace.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.